What question did this study set out to answer?

This research aims to assess the long-term efficacy of ibrutinib in treating chronic lymphocytic leukemia (CLL).

April 12, 2026Open Access

Ibrutinib: 10 years and counting

Puntos clave

This research aims to assess the long-term efficacy of ibrutinib in treating chronic lymphocytic leukemia (CLL).
10-year follow-up analysis of CLL patients treated with ibrutinib.
Focused on progression-free survival (PFS) in front line and relapsed cases.
Patient population included those with multihit TP53 aberration.
Median progression-free survival of 9 years in front line treatment.
Median progression-free survival of 4.1 years in relapsed CLL.
15.5% of patients achieved undetectable minimal residual disease (uMRD) at 5 years.

Resumen

In this issue of Blood, Itsara et al 1 report the 10-year follow-up of the treatment of chronic lymphocytic leukemia (CLL) with the first-in-class covalent Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, demonstrating a median progression-free survival (PFS) of 9 years in front line and 4.1 years in relapsed CLL.Unexpectedly 15.5% of patients achieved undetectable minimal residual disease (uMRD) at a median of 5 years.The study was enriched in patients with multihit TP53 aberration, whose survival outcomes were improved compared to historical data but were still shorter than those without the TP53 aberration. 1

Me gusta

Guardar

Ver artículo completo